EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oncotelic Therapeutics's enterprise value is $28.15 Mil.
Oncotelic Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.16 Mil. Therefore, Oncotelic Therapeutics's EV-to-EBITDA for today is -3.93.
The historical rank and industry rank for Oncotelic Therapeutics's EV-to-EBITDA or its related term are showing as below:
OTLC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.11 Med: 0.29 Max: 3.12
Current: -3.93
During the past 13 years, the highest EV-to-EBITDA of Oncotelic Therapeutics was 3.12. The lowest was -5.11. And the median was 0.29.
OTLC's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs OTLC: -3.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Oncotelic Therapeutics's stock price is $0.04.
Oncotelic Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.021. Therefore, Oncotelic Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Oncotelic Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Oncotelic Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncotelic Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncotelic Therapeutics EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Oncotelic Therapeutics's EV-to-EBITDA falls into.
Oncotelic Therapeutics EV-to-EBITDA Calculation
Oncotelic Therapeutics's EV-to-EBITDA for today is calculated as:
Oncotelic Therapeutics's current Enterprise Value is $28.15 Mil.
Oncotelic Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Oncotelic Therapeutics's PE Ratio for today is calculated as:
Oncotelic Therapeutics's share price for today is $0.04.
Oncotelic Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.021.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Oncotelic Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OTLC has been successfully added to your 